CLINICAL_TRIALS
trial_result
· 2024-09-03
Clinical Trial Update: LAMA2 Genetic Correction
Summary
A Maastricht University trial evaluating LAMA2 genetic correction for Merosin-deficient congenital muscular dystrophy type 1A (MDC1A) has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Snippet
Sponsor: Maastricht University | Conditions: MDC1A | Status: COMPLETED